JP2004508064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508064A5 JP2004508064A5 JP2002526335A JP2002526335A JP2004508064A5 JP 2004508064 A5 JP2004508064 A5 JP 2004508064A5 JP 2002526335 A JP2002526335 A JP 2002526335A JP 2002526335 A JP2002526335 A JP 2002526335A JP 2004508064 A5 JP2004508064 A5 JP 2004508064A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- adenoviral
- adenoviral vector
- vector
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013598 vector Substances 0.000 claims 89
- 241000701161 unidentified adenovirus Species 0.000 claims 51
- 229960005486 vaccine Drugs 0.000 claims 25
- 238000000034 method Methods 0.000 claims 23
- 230000002950 deficient Effects 0.000 claims 21
- 230000005030 transcription termination Effects 0.000 claims 21
- 230000014509 gene expression Effects 0.000 claims 20
- 230000010076 replication Effects 0.000 claims 20
- 239000002245 particle Substances 0.000 claims 17
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 229940033330 HIV vaccine Drugs 0.000 claims 12
- 229940021704 adenovirus vaccine Drugs 0.000 claims 10
- 230000004927 fusion Effects 0.000 claims 10
- 238000004806 packaging method and process Methods 0.000 claims 10
- 230000000295 complement effect Effects 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 108020004414 DNA Proteins 0.000 claims 8
- 230000004048 modification Effects 0.000 claims 8
- 238000012986 modification Methods 0.000 claims 8
- 239000013612 plasmid Substances 0.000 claims 8
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 108010057360 Adenovirus E1 Proteins Proteins 0.000 claims 6
- 241000701022 Cytomegalovirus Species 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 230000008488 polyadenylation Effects 0.000 claims 5
- 230000024932 T cell mediated immunity Effects 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 108010006025 bovine growth hormone Proteins 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 238000001890 transfection Methods 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108700026244 Open Reading Frames Proteins 0.000 claims 3
- 108700019146 Transgenes Proteins 0.000 claims 3
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 claims 3
- 108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 101710177291 Gag polyprotein Proteins 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 108010089520 pol Gene Products Proteins 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23318000P | 2000-09-15 | 2000-09-15 | |
| PCT/US2001/028861 WO2002022080A2 (en) | 2000-09-15 | 2001-09-14 | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004508064A JP2004508064A (ja) | 2004-03-18 |
| JP2004508064A5 true JP2004508064A5 (https=) | 2005-08-04 |
Family
ID=22876220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002526335A Withdrawn JP2004508064A (ja) | 2000-09-15 | 2001-09-14 | コドン最適化ｈｉｖ１−ｇａｇ、ｐｏｌ、ｎｅｆおよび修飾体を発現する増強された第１世代アデノウイルスワクチン |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1320621A4 (https=) |
| JP (1) | JP2004508064A (https=) |
| AU (2) | AU9456201A (https=) |
| CA (1) | CA2422882A1 (https=) |
| WO (1) | WO2002022080A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU782193B2 (en) * | 1999-12-17 | 2005-07-07 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef |
| CA2461380C (en) | 2001-10-11 | 2011-03-22 | Merck & Co., Inc. | Hepatitis c virus vaccine |
| CN1606625A (zh) | 2001-10-31 | 2005-04-13 | 南非医学研究会 | Hiv－1亚型分离株调节/附加基因及其修饰物和衍生物 |
| JP2005519959A (ja) * | 2002-03-13 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖに対する強化された免疫応答を誘導する方法 |
| EP1492891B1 (en) | 2002-03-29 | 2008-02-20 | Merck & Co., Inc. | Methods of virus production |
| DE60335672D1 (de) | 2002-05-14 | 2011-02-17 | Merck Sharp & Dohme | Verfahren zur reinigung von adenovirus |
| CN1490056A (zh) * | 2002-10-18 | 2004-04-21 | ��¡���ɵ°��̲��о����� | 针对hiv-1的免疫方法和组合物 |
| EP1553983A2 (en) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| WO2004055187A1 (en) | 2002-12-17 | 2004-07-01 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| AU2003294023B2 (en) | 2003-01-03 | 2008-01-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Rhesus HER2/neu, nucleotides encoding same, and uses thereof |
| CA2532460C (en) | 2003-07-21 | 2012-04-24 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
| GB2406336A (en) * | 2003-09-24 | 2005-03-30 | Oxxon Pharmaccines Ltd | HIV Pharmaccines |
| AU2005212479B2 (en) | 2004-02-11 | 2009-09-10 | Msd Italia S.R.L. | Carcinoembryonic antigen fusion proteins and uses thereof |
| NZ548495A (en) | 2004-02-23 | 2009-05-31 | Crucell Holland Bv | Virus purification methods |
| AU2005243730B2 (en) * | 2004-04-12 | 2010-05-27 | Genvec, Inc. | Method of using adenoviral vectors to induce an immune response |
| GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| BRPI0516048A (pt) | 2004-10-13 | 2008-08-19 | Crucell Holland B V E Beth Isr | batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c |
| DK1869171T4 (en) | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
| TW200716750A (en) * | 2005-05-12 | 2007-05-01 | Glaxo Group Ltd | Vaccine composition |
| AU2012201827B2 (en) * | 2005-05-12 | 2014-09-04 | Glaxo Group Limited | Vaccine composition |
| WO2007042169A2 (en) | 2005-10-07 | 2007-04-19 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Matrix metalloproteinase 11 vaccine |
| US9717788B2 (en) | 2007-03-02 | 2017-08-01 | Glaxosmithkline Biologicals Sa | Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant |
| HRP20161606T1 (hr) * | 2007-03-02 | 2017-01-13 | Glaxosmithkline Biologicals Sa | Novi postupak i pripravci |
| EP2047861B1 (en) * | 2007-10-12 | 2019-07-31 | Institut Pasteur | Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications |
| ES2708856T3 (es) | 2007-08-03 | 2019-04-11 | Pasteur Institut | Vectores de transferencia de gen lentivírico y sus aplicaciones medicinales |
| EP2185195A2 (en) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
| WO2010059732A1 (en) * | 2008-11-18 | 2010-05-27 | Beth Israel Deaconess Medical Center | Antiviral vaccines with improved cellular immunogenicity |
| AP2013007166A0 (en) | 2011-04-06 | 2013-10-31 | Univ Paris Descartes Inst De Rech Pour Le Dev Ird | Pharmaceutical compositions for preventing and/or treating an HIV disease in humans |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| JP5770952B2 (ja) | 2012-03-12 | 2015-08-26 | クルセル ホランド ベー ヴェー | 改変末端を有する組換えアデノウイルスのバッチ |
| EP4631509A3 (en) | 2012-11-16 | 2026-03-04 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
| ES2836432T3 (es) | 2015-03-18 | 2021-06-25 | Janssen Vaccines & Prevention Bv | Ensayos para sistemas de expresión recombinante |
| WO2016166088A1 (en) | 2015-04-14 | 2016-10-20 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
| KR102307065B1 (ko) | 2016-06-20 | 2021-09-30 | 얀센 백신스 앤드 프리벤션 비.브이. | 강력하고 균형 잡힌 양방향성 프로모터 |
| WO2019086450A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| WO2019086466A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| BR112020008435A2 (pt) | 2017-10-31 | 2020-11-17 | Janssen Vaccines & Prevention B.V. | vetores de adenovírus e seus usos |
| MA50502A (fr) | 2017-10-31 | 2020-09-09 | Janssen Vaccines & Prevention Bv | Adénovirus et utilisations associées |
| WO2019118480A1 (en) | 2017-12-11 | 2019-06-20 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
| CN111057716B (zh) * | 2019-07-27 | 2022-04-15 | 中国人民解放军军事科学院军事医学研究院 | 用于包装重组人4型腺病毒的单质粒载体系统及其应用 |
| IL291852A (en) | 2019-10-03 | 2022-06-01 | Janssen Vaccines & Prevention Bv | Adenovirus vectors and their use |
| CN112522276B (zh) * | 2020-12-15 | 2022-07-15 | 武汉纽福斯生物科技有限公司 | 一种emc1核苷酸序列及其应用 |
| WO2025242657A1 (en) | 2024-05-21 | 2025-11-27 | Shape Biopharmaceuticals Ag | Lipopeptide building blocks and aggregates |
| CN118931872B (zh) * | 2024-10-14 | 2025-05-20 | 南京诺唯赞生物科技股份有限公司 | Rna聚合酶变体及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643579A (en) * | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| AU3551195A (en) * | 1994-09-23 | 1996-04-09 | Somatix Therapy Corporation | Chimeric adenovirus for gene delivery |
| US5872005A (en) * | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
| WO1996039178A1 (en) * | 1995-06-05 | 1996-12-12 | The Wistar Institute Of Anatomy And Biology | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| AU6261696A (en) * | 1995-06-05 | 1996-12-24 | Trustees Of The University Of Pennsylvania, The | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| WO1999002647A2 (de) * | 1997-07-10 | 1999-01-21 | Hepavec Ag Für Gentherapie | Klonierungsvektoren für die herstellung von adenoviralen minimalviren |
| GB9803351D0 (en) * | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| US6670188B1 (en) * | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| AU6139699A (en) * | 1998-09-11 | 2000-04-03 | Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
| WO2000039302A2 (en) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| GB9906177D0 (en) * | 1999-03-17 | 1999-05-12 | Oxford Biomedica Ltd | Anti-viral vectors |
| GB9912965D0 (en) * | 1999-06-03 | 1999-08-04 | Oxford Biomedica Ltd | In vivo selection method |
| EP1242124A4 (en) * | 1999-12-22 | 2004-07-14 | Merck & Co Inc | POLYNUCLEOTIDE VACCINES EXPRESSING CODONE-OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL |
| ATE318908T1 (de) * | 2000-05-18 | 2006-03-15 | Geneart Gmbh | Synthetische gene für gagpol und deren verwendungen |
| WO2002032943A2 (en) * | 2000-08-14 | 2002-04-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
-
2001
- 2001-09-14 CA CA002422882A patent/CA2422882A1/en not_active Abandoned
- 2001-09-14 JP JP2002526335A patent/JP2004508064A/ja not_active Withdrawn
- 2001-09-14 AU AU9456201A patent/AU9456201A/xx active Pending
- 2001-09-14 WO PCT/US2001/028861 patent/WO2002022080A2/en not_active Ceased
- 2001-09-14 EP EP01975214A patent/EP1320621A4/en not_active Withdrawn
- 2001-09-14 AU AU2001294562A patent/AU2001294562B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004508064A5 (https=) | ||
| US11795477B2 (en) | Single cycle replicating adenovirus vectors | |
| CA2074502C (en) | Vaccines | |
| CA2461380A1 (en) | Hepatitis c virus vaccine | |
| JP2001511012A (ja) | 腫瘍崩壊性／免疫原性相補アデノウイルスベクター系 | |
| WO1998035028A9 (en) | An oncolytic/immunogenic complementary-adenoviral vector system | |
| Xu et al. | Construction of ovine adenovirus recombinants by gene insertion or deletion of related terminal region sequences | |
| WO1997012986A9 (en) | Non-group c adenoviral vectors | |
| WO1997012986A2 (en) | Non-group c adenoviral vectors | |
| WO2012172277A4 (en) | Simian adenovirus and hybrid adenoviral vectors | |
| CN121022880A (zh) | 重组腺病毒及其用途 | |
| JP2005505286A5 (https=) | ||
| JPH04501065A (ja) | 改良されたバキュロウイルス発現ベクター | |
| CA2189067A1 (en) | Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line | |
| KR20160102024A (ko) | 아데노바이러스 및 상응하는 플라스미드의 제조 방법 | |
| US7001760B2 (en) | Hepatitis B virus vectors for gene therapy | |
| CA2461579A1 (en) | Porcine adenovirus e1 region | |
| CN100471957C (zh) | 用于免疫治疗的腺病毒载体 | |
| WO2004097016A1 (en) | Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby | |
| Hokanson et al. | Hybrid yeast–bacteria cloning system used to capture and modify adenoviral and nonviral genomes | |
| CA2463996A1 (en) | Replication competent dual-ad vectors for vaccine and immunotherapy applications | |
| JP2002541815A (ja) | ウシアデノウイルス１型から誘導された組換えアデノウイルスおよび変異アデノウイルス |